Pancreatic cancer has one of the lowest five-year survival rates of any malignancy, partly because the molecular mechanisms driving tumor development remain incompletely understood. Identifying which biological processes and pathways are most dysregulated can point researchers toward better diagnostic markers and therapeutic targets.
Gene Ontology (GO) terms are standardized labels that describe what a gene's product does, where it operates inside a cell, and which biological processes it participates in. When researchers compare which GO terms appear far more often among cancer-related genes than expected by chance, they reveal the cellular functions most central to the disease.
KEGG pathway databases map genes onto known biochemical networks, from cell-cycle regulation and DNA repair to metabolic cascades. Enrichment analysis asks which of these pre-defined networks are statistically over-represented among differentially expressed or disease-associated genes, turning a long gene list into interpretable biology.
The study applied minimum Redundancy Maximum Relevance (mRMR), a feature-selection algorithm that simultaneously maximizes the statistical association between each selected feature and the target outcome (pancreatic cancer) while minimizing redundancy among the selected features themselves.
Starting from a large collection of candidate GO terms and pathways, mRMR iteratively picks the next feature that adds the most new information relative to the features already chosen. This prevents the final set from being dominated by highly correlated entries that would effectively repeat the same signal.
Compared to ranking features purely by individual correlation with outcome, mRMR produces a compact, non-redundant set that is better suited for downstream modeling and biological interpretation. In this study it was applied to pancreatic-cancer gene expression data to distill the most discriminative molecular signatures.
The analysis identified 17 KEGG pathways that were significantly enriched among genes linked to pancreatic cancer. These span core oncogenic processes including cell proliferation, apoptosis evasion, signal transduction, and metabolic reprogramming.
Several of the top-ranked pathways involve well-known cancer-driving cascades such as the MAPK, PI3K-Akt, and p53 signaling pathways, consistent with the genomic landscape of pancreatic ductal adenocarcinoma where mutations in KRAS and TP53 are nearly universal.
Pathway-level enrichment provides broader functional context than single-gene analysis. Knowing that an entire signaling network is dysregulated helps prioritize combination therapies that target multiple nodes simultaneously rather than relying on any single gene or protein as a biomarker.
From the GO analysis, five GO terms were selected by mRMR as the most informative descriptors of pancreatic-cancer biology. These terms captured molecular functions and biological processes most distinctly altered in tumor tissue compared with normal pancreatic cells.
GO terms related to cell proliferation, apoptotic processes, and enzymatic activity regulation featured prominently, reflecting the fundamental biology of uncontrolled growth and survival advantage that characterizes malignant transformation in the pancreas.
The small number of top-ranked terms is practically important. A focused set of five GO terms is far more tractable for experimental follow-up and clinical translation than a diffuse list of hundreds, giving researchers clear targets for mechanistic study and biomarker validation.
The convergence of multiple dysregulated pathways around a small number of GO terms suggests that pancreatic cancer rewires cellular biology in a coordinated rather than random manner. This systems-level view can inform the design of multi-target therapeutic strategies aimed at blocking the entire rewired network rather than a single node.
From a diagnostic standpoint, the identified GO terms and KEGG pathways could serve as the basis for expression-based classifiers that distinguish cancerous from normal pancreatic tissue, supporting earlier detection in high-risk populations such as patients with new-onset diabetes or a family history of pancreatic cancer.
The mRMR methodology applied here is generalizable to other cancer types and omics data modalities. Future work could integrate proteomics, methylation, or single-cell RNA-sequencing data with the same feature-selection framework to build richer, more accurate molecular portraits of pancreatic cancer progression.